AP
LYEL icon

Adero Partners’s Lyell Immunopharma LYEL Stock Holding History

Adero Partners’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$7.02K Hold
652
– – ﹤0.01% 259
2024
Q4 		$8.35K Sell
652
-391
-37% -$7.75K ﹤0.01% 262
2024
Q3 		$28.8K Hold
1,043
– – ﹤0.01% 239
2024
Q2 		$30.3K Hold
1,043
– – ﹤0.01% 218
2024
Q1 		$46.5K Hold
1,043
– – ﹤0.01% 203
2023
Q4 		$40.5K Hold
1,043
– – ﹤0.01% 191
2023
Q3 		$30.7K Buy
1,043
+391
+60% +$18.6K ﹤0.01% 180
2023
Q2 		$41.5K Hold
652
– – ﹤0.01% 164
2023
Q1 		$30.8K Hold
652
– – ﹤0.01% 161
2022
Q4 		$45.3K Hold
652
– – 0.01% 161
2022
Q3 		$84K Buy
+652
New +$88.3K 0.01% 153
2022
Q2 		– Sell
-12,676
Closed -$1.28M – 158
2022
Q1 		$1.28M Sell
12,676
-11,893
-48% -$1.44M 0.19% 57
2021
Q4 		$3.8M Buy
+24,569
New +$5.48M 0.62% 33

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Adero Partners's LYEL Position: Q1 2025 in Review

Adero Partners held its Lyell Immunopharma (LYEL) position steady in Q1 2025 at 652 shares worth $7.02K. The position accounts for ﹤0.01% of the portfolio, ranked #259.

Adero Partners first reported a position in LYEL in Q4 2021 and has held it in 13 quarters since. The position peaked at $3.8M in Q4 2021. 112 funds tracked by Wall St. Rank hold LYEL as of Q1 2025.

  • Adero Partners held 652 shares of Lyell Immunopharma worth $7.02K as of Q1 2025.
  • Adero Partners left its Lyell Immunopharma share count unchanged in Q1 2025.
  • Lyell Immunopharma made up ﹤0.01% of Adero Partners's portfolio in Q1 2025, its #259 holding.
  • Adero Partners first reported a position in Lyell Immunopharma in Q4 2021 and has held it in 13 quarters since.
  • Adero Partners's Lyell Immunopharma position peaked at $3.8M in Q4 2021.
  • 112 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2025.

Based on Adero Partners's 13F filing for Q1 2025, filed 17 Apr 2025.